ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2010
Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- An In Vitro Evaluation of a New Approach in AMD: Effects of the Combination of Resveratrol and Anti-VEGFs on ARPE-19 Cells.Biomolecules · 2026Article
- Modified autologous neurosensory retinal transplantation and bevacizumab injection in primary extra-large chronic macular holes.American journal of ophthalmology case reports · 2025Article
- Differential effects of risuteganib and bevacizumab on AMD cybrid cells.Experimental eye research · 2021Article
- Hypo-angiogenesis: a possible pathological factor in the development of dry age-related macular degeneration and a novel therapeutic target.Medical hypothesis, discovery & innovation ophthalmology journal · 2021Article
- In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs.Experimental eye research · 2020Article
- Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.Experimental eye research · 2018Article
- Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells.Scientific reports · 2017Article
- Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.International journal of molecular sciences · 2017Article
- The effects of anti-vascular endothelial growth factor agents on human retinal pigment epithelial cells under high glucose conditions.International journal of ophthalmology · 2017Article
- Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.BMC research notes · 2014Article
- Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results.Indian journal of ophthalmology · 2014Observational
- Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.The British journal of ophthalmology · 2012Article
- Expression and role of VEGF in the adult retinal pigment epithelium.Investigative ophthalmology & visual science · 2011Article
- Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?Drugs & aging · 2011Article
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.Eye (London, England) · 2011Review
- Effects of anti-VEGF agents on rat retinal Müller glial cells.Molecular vision · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have previously shown that bevacizumab, but not ranibizumab, is taken up by porcine RPE cells. In this study, the effects of bevacizumab and ranibizumab on proliferation, wound healing and phagocytosis of the RPE were investigated.
methodsPrimary porcine RPE cell culture were prepared from fresh eyes, cultivated and treated with clinically relevant concentrations of bevacizumab or ranibizumab respectively. Proliferation was investigated in a proliferation assay, wound healing in a wound scratch assay and phagocytosis was investigated by feeding RPE cells photoreceptor outer segment-opsonized FITC-labeled latex beads.
resultsBevacizumab, and to a lesser extend ranibizumab, impair the proliferation of RPE cells but do not affect wound healing. Bevacizumab, but not ranibizumab, reduces the phagocytotic function of RPE cells.
conclusionsThe uptake of bevacizumab reduces phagocytosis in RPE cells, which indicates possible long-term effects of repeated bevacizumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.